83 related articles for article (PubMed ID: 14998077)
1. Morphostructural damage and the inhibition of bacterial adhesiveness of Staphylococcus aureus and Moraxella catarrhalis induced by moxifloxacin.
Braga PC; Culici M; Ricci D; Dal Sasso M
J Chemother; 2003 Dec; 15(6):543-50. PubMed ID: 14998077
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
Jacobs E; Dalhoff A; Korfmann G
Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
[TBL] [Abstract][Full Text] [Related]
3. Favourable effects of sub-MIC rufloxacin concentrations in decreasing the pathogen-host cell adhesion.
Braga PC; Piatti G
Pharmacol Res; 1993; 28(1):11-9. PubMed ID: 8234142
[TBL] [Abstract][Full Text] [Related]
4. Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone.
Drago L; De Vecchi E; Nicola L; Tocalli L; Gismondo MR
J Chemother; 2004 Feb; 16(1):30-7. PubMed ID: 15077996
[TBL] [Abstract][Full Text] [Related]
5. Staphylococcus aureus and Escherichia coli adhesion to human cells is reduced by sub-MICs of gemifloxacin.
Braga PC; Dal SM; Woodnutt G
J Chemother; 2002 Feb; 14(1):41-6. PubMed ID: 11892898
[TBL] [Abstract][Full Text] [Related]
6. Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary pathogens isolated from patients with community-acquired bacterial pneumonia.
Biedenbach DJ; Farrell DJ; Flamm RK; Liverman LC; McIntyre G; Jones RN
Int J Antimicrob Agents; 2012 Apr; 39(4):321-5. PubMed ID: 22306239
[TBL] [Abstract][Full Text] [Related]
7. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
[TBL] [Abstract][Full Text] [Related]
8. Effects of sub-minimum inhibitory concentrations of gatifloxacin on the inhibition of Staphylococcus aureus and Escherichia coli adherence.
Braga PC; Dal Sasso M
Arzneimittelforschung; 2002; 52(2):109-12. PubMed ID: 11878198
[TBL] [Abstract][Full Text] [Related]
9. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination.
Firsov AA; Vostrov SN; Lubenko IY; Portnoy YA; Zinner SH
Int J Antimicrob Agents; 2004 May; 23(5):451-6. PubMed ID: 15120722
[TBL] [Abstract][Full Text] [Related]
10. Influence of moxifloxacin, comparator drugs and some fractions of pulmonary surfactant on adherence of some respiratory pathogens.
Ferrara A; Dos Santos C; Tellarini MT
Infection; 2002 Aug; 30(4):208-11. PubMed ID: 12236562
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.
Elshafie SS; Al-Kuwari J
Int J Antimicrob Agents; 2004 Sep; 24(3):309-10. PubMed ID: 15325441
[No Abstract] [Full Text] [Related]
13. Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2007 Nov; 30(5):415-21. PubMed ID: 17768034
[TBL] [Abstract][Full Text] [Related]
14. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.
Lemaire S; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2011 Feb; 55(2):649-58. PubMed ID: 21135179
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of bacterial adhesion by sub-inhibitory concentrations: brodimoprim vs trimethoprim.
Braga PC; Piatti G; Limoli A; Santoro M; Gazzola T
J Chemother; 1993 Dec; 5(6):447-52. PubMed ID: 8195836
[TBL] [Abstract][Full Text] [Related]
16. Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
Shi G; Chen X; Wang H; Wang S; Guo X; Zhang X
J Antibiot (Tokyo); 2012 May; 65(5):229-36. PubMed ID: 22334239
[TBL] [Abstract][Full Text] [Related]
17. Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro.
Ulrich M; Berger J; Möller JG; Döring G
Infection; 2005 Dec; 33 Suppl 2():50-4. PubMed ID: 16518712
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Oliveira AD; D'Azevedo PA; Francisco W
Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility comparisons of normal preoperative conjunctival bacteria to fluoroquinolones.
Hori Y; Nakazawa T; Maeda N; Sakamoto M; Yokokura S; Kubota A; Inoue T; Nishida K; Tano Y
J Cataract Refract Surg; 2009 Mar; 35(3):475-9. PubMed ID: 19251140
[TBL] [Abstract][Full Text] [Related]
20. Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial.
Farrell DJ; Turner LL; Castanheira M; Jones RN
Diagn Microbiol Infect Dis; 2012 Sep; 74(1):73-4. PubMed ID: 22819242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
